Sanofi's big dermatology hope fails in phase III
One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
As things appear at the moment, Sanofi hasn't achieved its ambitions with drug rilzabrutinib that management had otherwise hoped when the French pharmaceutical company acquired the compound via its acquisition of Prinicipia Biopharma in 2020.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
